Mitochondrial potassium channels, such as ATP-regulated or large conductance Ca 2+ -activated and voltage gated channels were implicated in cytoprotective phenomenon in different tissues. Basic effects of these channels activity include changes in mitochondrial matrix volume, mitochondrial respiration and membrane potential, and generation of reactive oxygen species. In this paper, we describe the pharmacological properties of mitochondrial potassium channels and their modulation by channel inhibitors and potassium channel openers. We also discuss potential side effects of these substances.
Introduction
Mitochondria play a fundamental role in energy generation within the cell. Apart from this canonical role, mitochondria are involved in other complex processes such as apoptosis. Mitochondrial membrane permeabilization induces the release of cytochrome c, Smac/DIABLO, and AIF, starting various apoptosis pathways. Recently, an essential position of potassium transport through mitochondrial inner membrane was identified to trigger cytoprotection [1] [2] [3] . This transport is strictly ion channel dependent, and accordingly, resembles plasma membrane ion channels activity. Potassium selective ion channels were found to be present in inner mitochondrial membrane [4] [5] [6] . Potassium ions control mitochondrial metabolism primarily due to the regulation of matrix volume [7] . The basic pharmacological properties of mitochondrial potassium channels such as ATP-regulated potassium (mitoK ATP ) channel, large conductance Ca 2+ -activated potassium (mitoBK Ca ) channel and voltage dependent potassium (mitoKv1.3) channel were found to be similar to some of the potassium channels present in the plasma membrane of various cell types [8] .
Rational application of different pharmacological substances (channel inhibitors or potassium channel openers) helps in explaining the functional role of mitochondrial potassium channels within the cell. In this paper, we describe the properties of mitochondrial potassium channels, their modulation by channel inhibitors and activators (potassium channel openers). Finally, we also discuss side effects of these substances and their potential contribution to cytoprotective effects.
Mitochondrial ATP-regulated K + channel
The mitoK ATP channel was initially described in isolated liver mitochondria [9] . Subsequently, it was also identified in heart [10] , brain [11, 12] , renal [13] , skeletal muscle [14] and human T-lymphocyte mitochondria [15] . The activity of this channel is modulated by various nucleotides [10] (see Fig. 1 ). Recently, it was shown that ATP effects on the mitoK ATP channel can be modulated by Ca 2+ [15] .
The molecular identity of the mitoK ATP channel is presently unknown. Immunological studies identify both pore forming Kir 6.1 and Kir6.2 subunits in brain mitochondria [16] . It has also been hypothesized that a complex of five proteins (including succinate dehydrogenase) in the mitochondrial inner membrane is capable of transporting K + with characteristics similar to those of the mito-K ATP channel [17] . Recently, adenine nucleotide translocase was implicated in ATP-sensitive K + transport into mitochondria [18] [19] [20] . Interestingly, the involvement of adenine nucleotide translocase in K + traffic was also suggested before description of the K ATP channel activity in inner mitochondrial membrane [20] .
Similarly, molecular properties of the mitochondrial sulfonylurea receptor (mitoSUR) are also not clear. The use of the sulfonylurea derivative [
125 I]glibenclamide leads to labeling of a 28 kDa protein in heart mitochondria [21] . A 64 kDa protein was labeled in brain mitochondria with the use of the fluorescent probe BODIPY-glibenclamide [11] .
Activity of this channel is modulated by drugs known as potassium channel openers [22] . All of the potassium channel openers applied on mitochondria were previously used to regulate plasma membrane ATP-regulated potassium channel or large conductance calcium-activated potassium channel. Despite this, potassium channel openers such as diazoxide and BMS191095, are considered mitoK ATP -selective openers. Similarly, 5-hydroxydecanoic acid has some mitochondrial specificity as mitoK ATP channel blocker.
An important contribution to understanding the pharmacological properties of the mitoK ATP channel comes from the use of the techniques allowing single channel recording i.e. patch clamp or black lipid membranes [9, 15, [23] [24] [25] . The observed K + channel activity is in fact a mitoK ATP channel if the following pharmacological properties are present in the recorded potassium channel:
(1) The channel has to be blocked by ATP/Mg [9, 10, 23, 26] , (2) The ATP/Mg-inhibited channel should be activated by the potassium channel opener diazoxide [26, 27] , (3) The channel should be blocked by 5-hydroxydecanoic acid (5-HD), a substance known to be a blocker of the mitochondrial channel [23, 24, 26] , (4) The channel should be blocked by glibenclamide [9, 10, 26] , (5) The plasma membrane cardiac K ATP channel blocker HMR1098 should be without effect on the channel activity [23, 28] , Some of the substances acting on mitoK ATP show additional effect on isolated mitochondria. Diazoxide is known to inhibit mitochondrial succinate dehydrogenase [29] and induce uncoupling of mitochondria [30, 31] . Similar effects were observed with potassium channel opener-pinacidil [30] . Glibenclamide is also able to uncouple mitochondria at a high concentration [32] or to induce mitochondrial permeability transition [33] . Recently, it was shown that 5-HD is rapidly converted to 5-HD-CoA by mitochondrial fatty acyl-CoA synthetase and acts as a weak substrate or inhibitor of respiration in the employed conditions [34, 35] . Hence, in some reports the existence of the mitoK ATP channel in inner mitochondrial membrane is questioned [19, [35] [36] [37] . It is proposed that the pharmacological preconditioning by mitoK ATP channel modulators may be related to partial inhibition of respiratory chain complexes [35, 38] .
These side effects may contribute to the overall effects of substances used in experimental models with active metabolism, for example in experiments on isolated mitochondria or cells (see Table 1 ). For example, application of 5-HD, as the K ATP channel blocker, may be questioned in experimental models with active acyl-CoA synthase [35] . Additionally, the channel opener -diazoxide -has a complex action on mitochondrial membrane potential [39] , ROS production [40] and mitochondrial permeability transition pore [41] .
Mitochondrial large conductance calcium-activated potassium channel
A putative mitochondrial large conductance Ca 2+ -activated potassium channel (mitoBK Ca channel) was originally described using patch-clamp technique in human glioma cells LN229 [42] . This channel, with a conductance of 295 pS, was stimulated by Ca 2+ and blocked by charybdotoxin. Later the presence of a channel with properties similar to the surface membrane calciumactivated K + channel (stimulated by the potassium channel opener NS1619 and blocked by charybdotoxin, iberiotoxin and paxilline) was observed in patch-clamp recordings from mitoplasts of guinea pig ventricular cells [43] . Immunoblots of cardiac mitochondria with antibodies against the C terminal part of BK Ca channel identified a 55 kDa protein as putative channel which may contribute to the cardioprotective effect of K + influx into mitochondria. Very recently, it was reported that cardiac mito BK Ca activation by NS1619 (measured by flavoproteins oxidation) is amplified by 8-bromoadenosine-3′,5′-cyclic monophosphate and forskolin [44] . This suggests that opening of mitoBK Ca is modulated by cAMP-dependent protein kinase.
It should be mentioned that the mitoBK Ca channel may offer a novel link between cellular/mitochondrial calcium signaling and mitochondrial membrane potential-dependent reactions. Altered intramitochondrial calcium levels directly affect the potassium permeability of the mitochondrial inner membrane thus modulating the membrane potential. This type of interaction can modulate the efficiency of oxidative phosphorylation in a calciumdependent manner.
The pharmacological, biophysical and molecular characteristics of this channel appear to be similar to the following properties of the well known plasma membrane large conductance potassium channel (BK Ca -channel, slo 1) [45] :
(i) The mitochondrial channel is potassium selective and activated by calcium ions. (ii) The channel is inhibited by iberiotoxin and charybdotoxin at nanomolar concentrations. (iii) The channel is activated by NS1619 at low micromolar concentrations.
Very likely, the mitochondrial channel has its charybdotoxin/ iberiotoxin binding site close to the cytosolic compartment since those compounds as peptides cannot easily enter the mitochondrial matrix space. Consequently, the calcium binding site of the mitoBK Ca channel is close to the matrix compartment (cf. orientation of the plasma membrane BK Ca channel [45] ).
Similar to the mitochondrial ATP-regulated potassium channel, this novel potassium channel is expected to affect mitochondrial metabolism due to regulation of matrix volume [7] . In addition to this classical physiological effect of mitochondrial potassium transport, a pivotal role of mitochondrial potassium channels has been implicated in cardio-and neuroprotection [1, 2, 46] . It is therefore reasonable to expect a possible cytoprotective effect of mitoBK Ca channel activation, probably in the presence of superoxide radicals [47] . Recently, it was shown that cardioprotective effects of estradiol include the activation of mitoBK Ca channel in cardiac mitochondria [48] . Additionally, it was suggested that the β1 subunit of BK Ca channel is present in inner mitochondrial membrane and interacts with cytochrome c oxidase subunit I [48] .
It has also been reported that two BK Ca channel openers, NS004 and NS1619, inhibit mitochondrial function in human glioma cells due to inhibition of the complex I of mitochondrial respiratory chain [49] . Recently, a channel opener NS1619 was shown to inhibit the function of isolated cardiac mitochondria in similar manner [50] .
Voltage regulated potassium channel in inner mitochondrial membrane
Recently, a margatoxin-sensitive voltage gated Kv1.3 channel was identified in T lymphocytes mitochondria [51] with the use of patch-clamp, electron microscopy and immunological studies. Interestingly, it was shown that Kv1.3 is present both in the plasma and mitochondrial membranes, despite lacking the N-terminal mitochondrial targeting sequence. Mitochondrial Kv1.3 channel my represent an important factor in the apoptotic signal transduction [51] .
Final remarks
Until presently, three different potassium channels have been reported to contribute to the potassium permeability of mitochondria-the ATP-regulated potassium channel (mitoK ATP channel), the large conductance Ca 2+ -activated potassium channel (mitoBK Ca channel) and the voltage gated Kv1.3 channel. Although the precise molecular identity of these channels remains to be elucidated, their control of mitochondrial potassium transport has two important implications:
Small alterations in the potassium permeability contribute to physiological regulation of the mitochondrial matrix volume.
A larger increase in the potassium permeability of the mitochondrial inner membrane affects the mitochondrial membrane potential (mild uncoupling) with potential beneficial effects on cell survival under pathological conditions.
In this review, various classes of substances that interact with mitochondrial potassium channels have been presented. They play an important role in identification and characterization of mitochondrial channels in different tissues. In light of the ubiquitous presence of mitochondrial identified potassium channels, novel opportunities for novel drug development have been emerged. To reach this stage, however, the molecular identification of Patch-clamp 2 nM Studies were performed on T lymphocytes mitochondria [51] Isolated mitochondria 10 nM A relatively high concentration of toxin was used to promote a rapid diffusion to the inner membrane and to achieve complete inhibition [51] mitochondrial potassium channels (especially mitoK ATP channel) requires significant progress. Moreover, drugs specific to the new mitochondrial channels (lacking cross-reactivity with plasma membrane channels or other enzymes present in mitochondria) will have to be synthesized.
